Rezolute, Inc. Stock Other OTC
Stocks
US76200L1017
Biotechnology & Medical Research
| Market Cap | 521M 458M 426M 391M 734M 50.2B 745M 5.06B 1.98B 24.68B 1.96B 1.91B 85.33B | P/E 2026 * |
-7.13x | P/E 2027 * | -7.68x |
|---|---|---|---|---|---|
| Enterprise Value | 521M 458M 426M 391M 734M 50.2B 745M 5.06B 1.98B 24.68B 1.96B 1.91B 85.33B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 226x |
| Free-Float |
89.85% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Rezolute, Inc.
| 1 day | +5.51% |
| Manager | Title | Age | Since |
|---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 58 | 2013-01-29 |
Daron Evans
DFI | Director of Finance/CFO | 52 | 2024-01-22 |
Michael Deperro
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Nevan Elam
CHM | Chairman | 58 | 2022-05-03 |
Gil Labrucherie
BRD | Director/Board Member | 55 | 2019-11-19 |
Young-Jin Kim
CHM | Chairman | 68 | 2019-02-09 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.51% | -3.90% | - | - | 521M | |
| +0.93% | +6.97% | +59.60% | +68.35% | 57.28B | |
| -1.92% | +6.03% | +40.64% | +83.42% | 54.99B | |
| -0.46% | -1.29% | +2.86% | +428.78% | 23.18B | |
| -2.97% | -2.35% | -22.53% | -16.40% | 22.59B | |
| -0.36% | +5.73% | +24.13% | -6.24% | 20.46B | |
| -1.34% | +0.51% | +26.03% | -29.41% | 17.56B | |
| -1.44% | +5.67% | +38.77% | +504.71% | 15.67B | |
| -1.30% | -5.02% | +170.77% | +291.37% | 14.46B | |
| -0.50% | -0.98% | +21.43% | +180.07% | 13.92B | |
| Average | -0.39% | +1.28% | +40.19% | +167.18% | 26.68B | |
| Weighted average by Cap. | -0.86% | +2.10% | +39.70% | +133.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 2.3M 2.02M 1.88M 1.73M 3.24M 222M 3.29M 22.35M 8.73M 109M 8.65M 8.46M 377M |
| Net income | -72.7M -63.85M -59.38M -54.49M -102M -7B -104M -705M -275M -3.44B -273M -267M -11.9B | -75.12M -65.98M -61.36M -56.3M -106M -7.23B -107M -729M -285M -3.56B -282M -276M -12.3B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
